Guidelines on Hypertension 2013 (TF31) - TF …19/05/2013 Same relationships as last year, i.e., no...

Boehm Michael A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Cardiolgoy (2011-2012) - Astra Zeneca : Cardiology (2011-2012)

- Daiichi Sankyo : Cardiology (2011-2012)

- Medtronic : Cardiology (2011-2012)

- Novartis : Cardiology (2011-2012)

- Pfizer : Cardiology (2011-2012)

- Servier : Cardiology (2011-2012)

- Sanofi Aventis : Cardiology (2011-2012)

- Bayer AG : Cardiology (2011-2012)

- MSD : Cardiology (2011-2012)

D - Research funding (departmental or institutional). - Boehringer-Ingelheim : Cardiology (2011-2012) - Medtronic : Cardiology (2011-2012)

- Novartis : Cardiology (2011-2012)

- Pfizer : Cardiology (2011-2012)

- Servier : Cardiology (2011-2012)

- Sanofi Aventis : Cardiology (2011-2012)

- Bayer AG : Cardiology (2011-2012)

14/05/2013 same relationships as 2012

Additional Information declared for 2013 January - May

1/2014/06/2013

Guidelines on Hypertension 2013 (TF31) - TF Members and Additional Contributors

Expert Type of Relationship with Industry

karine_villanese

Typewritten Text

Christiaens Thierry None

Cifkova Renata A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular (2010-2011) - Daiichi Sankyo : cardiovascular (2010)

- Medtronic : cardiovascular (2012)

- MSD-SP, Boehringer Ingelheim, Bayer : cardiovascular (2010)

- Berlin Chemie AG : cardiovascular (2012)

- Actavis : cardiovascular (2011)

- Merck Sharp & Dohme : cardiovascular (2012)

- Zentiva : cardiovascular (2011)

- Teva Pharmaceutical Industries : cardiovascular (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular (2011) - Daiichi Sankyo : cardiovascular (2010)

- Novartis : cardiovascular (2012)

- Novartis : cardiovascular (2010-2011)

D - Research funding (departmental or institutional). - Servier : cardiovascular (2010) - Krka : cardiovascular (2012)

- Krka : cardiovascular (2010-2011)

13/05/2013 No changes to declare

19/05/2013 Same relationships as last year, i.e., no changes to declare.


2/2014/06/2013



De Backer Guy A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Advisory board (2010-2011-2012) - Merck Sharp & Dohme : Advisory board (2010-2011)

- MSD : Advisory board (2012)

- Abbott : member of publication committee POWER study (2011)



Dominiczak Anna F A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Genomics, i.e. N/A (2010) - Servier International : Hypertension/Cardiovascular prevention (2011-2012)

- American Heart Association : N/A Journal - Hypertension (2010)

- British Heart Foundation, Wellcome Trust, Medical Research Council : N/A (2010)

14/05/2013 Same relationships as 2012 i.e. no changes to declare.


Fagard Robert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None

3/2014/06/2013



Fagard Robert - Servier : Honorarium for manuscript (2011)

- Servier : Honorarium for manuscript in Medicographia (2010)



Galderisi Maurizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Menarini : Cardiac therapy (2010)

19/05/2013 No changes to financial interests or positions of influence since my last annul declaration


Grobbee Diederick E A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche Pharma : cardiovascular (2011-2012) - Servier : cardiovascular metabolic (2010)

- Roche Pharma : cardiovascular metabolic (2010)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche Pharma : cardiovascular (2011-2012) - Pfizer : cardiovascular metabolic (2010)

- Roche Pharma : cardiovascular risk, diabetes (2010)

4/2014/06/2013



Grobbee Diederick E D - Research funding (departmental or institutional). - Novartis : cardiovascular (2011-2012) - Roche Pharma : Cardiovascular (2011-2012)

- Roche Pharma : cardiovascular metabolic (2010)

- Pfizer : infectious diseases (2010)

- Astra Zeneca : primary and secondary prevention of vascular disease, imaging (2010)

- Novartis : renal diabetes (2010)

- Pfizer : vaccines (2011-2012)

Jaarsma Tiny A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Vifor International : IV iron (2010)

- Vifor International : IV iron (2010)

13/05/2013 Guidelines on Hypertension 2013 (TF31)

14/05/2013 same relationships as last year i.e. no changes to declare

14/05/2013 no changes


Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - EHRA : arrhythmia management (2010) - BMS : cardiovascular (2011-2012)

- Boehringer-Ingelheim : cardiovascular (2011-2012)

- Daiichi Sankyo : cardiovascular (2011-2012)

- Medtronic : cardiovascular (2011-2012)

5/2014/06/2013



karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

No additional information for the 2013 January - May period has been submitted

Kirchhof Paulus - Pfizer : cardiovascular (2012)

- St Jude Medical : cardiovascular (2011-2012)

- Sanofi Aventis : cardiovascular (2011)


- Meda pharma : cardiovascular (2011-2012)

- Merck Sharp & Dohme : cardiovascular (2011-2012)

- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011-2012)

- Boston Scientific : cardiovascular devices (2010)

- Medtronic : cardiovascular devices (2010)

- St Jude Medical : cardiovascular devices (2010)

- Biotronik : cardiovascular devices (2010)

- Cordis : cardiovascular devices (2010)

- Astra Zeneca : cardiovascular drugs (2010)

- Bayer : cardiovascular drugs (2010)

- Boehringer-Ingelheim : cardiovascular drugs (2010)

- Daiichi Sankyo : cardiovascular drugs (2010)

- Sanofi Aventis : cardiovascular drugs (2010)

- GlaxoSmithKline : cardiovascular drugs (2010)

- BMS/Pfizer : cardiovascular drugs (2010)

- Meda pharma : cardiovascular drugs (2010)

- Abbott Vascular : cardiovascular drugs (2010)

- Takeda Pharmaceuticals : cardiovascular drugs (2010)

- Bristol Myers Squibb : cardiovascular drugs (2010)

- 3M : cardiovascular drugs (2010)

6/2014/06/2013



Kirchhof Paulus - Merck Sharp & Dohme : cardiovascular drugs (2010)

- Oxford University Press : heart disease management (2010)

- WebMD : heart disease management (2010)

- Heart.org : management of heart disease (2010)

- Boehringer-Ingelheim : cardiovascular (2012)

- Bayer Healthcare : cardiovascular (2012)

- Portola Pharmaceuticals : cardiovascular (2012)

- BMS / Pfizer alliance : cardiovascular (2012)

D - Research funding (departmental or institutional). - European Union : atrial fibrillation (2010) - Fondation Leducq : atrial fibrillation (2010)

- St Jude Medical : cardiovascular (2011-2012)

- Sanofi Aventis : cardiovascular (2011-2012)

- Meda pharma : cardiovascular (2012)


- St Jude Medical : cardiovascular devices (2010)

- OMRON Healthcare : cardiovascular devices (2010)

- Sanofi Aventis : cardiovascular drugs (2010)

- 3M / MEDA Pharma : cardiovascular drugs (2010)

- Cardiovascular Therapeutics : cardiovascular drugs (2010)

- Deutsche Forschungsgemeinschaft : heart disease (2010)

14/05/2013 Consulting fees and honoraria3M MedicaMEDA Pharma


7/2014/06/2013



AstraZenecaBayer HealthcareBiosense WebsterBoehringer IngelheimDaiichi-SankyoGerman Cardiac SocietyMEDA PharmaMedtronicMerckMSDOtsuka PharmaPfizer / BMSsanofiServierSiemensTAKEDA

In addition, I have received travelsupport for meetings from theEuropean Society of Cardiology (ESC),the European Heart RhythmAssociation (EHRA), a registeredbranch of ESC, and from the GermanAtrial Fibrillation CompetenceNETwork (AFNET)

Research Grants3M Medica / MEDA PharmaCardiovascular TherapeuticsMedtronicOMRONSANOFISt. Jude MedicalGerman Federal Ministry forEducation and Research (BMBF)Fondation LeducqGerman Research Foundation (DFG)

8/2014/06/2013



European Union (EU)

Kjeldsen Sverre Erik A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Equipment (2010-2011-2012) - Boehringer-Ingelheim : Medical equipment (2010)

- Bayer Healthcare : Pharma (2011-2012)

- Bayer Healthcare : Pharma (2010)

- Takeda Pharmaceuticals : Pharma (2010-2011-2012)

- Merck Sharp & Dohme : Pharma (2012)

- Serodeus : Pharma (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Pharma (2010-2011-2012) - Pronova Bioscience : Pharma (2010-2011-2012)

D - Research funding (departmental or institutional). - Norwegian Government : Public Health System (2012) - Norwegian Government : Public Health System (2010-2011)

E - Research funding (personal). - Norwegian Council for Cardiovascular Diseases : Foundation for Cardiovascular Research (2010-2011-2012)

Laurent Stephane A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : antihypertensive drugs (2010-2011-2012) - Daiichi Sankyo : antihypertensive drugs (2010-2011-2012)

- Novartis : antihypertensive drugs (2010-2011-2012)

- Servier : antihypertensive drugs (2010-2011-2012)

- Chiesi Pharma : antihypertensive drugs (2010-2011-2012)

- Recordati International : antihypertensive drugs (2010-2011-2012)

9/2014/06/2013



karine_villanese

Typewritten Text


Laurent Stephane - OMRON Healthcare : Manufacturer, apparatus for blood pressure measurement (2011-2012)

- Esaote : Manufacturer, apparatus for blood pressure measurement (2011-2012)

- ATCOR : Manufacturer, apparatus for blood pressure measurement (2011-2012)

D - Research funding (departmental or institutional). - Servier : antihypertensive drugs (2010-2011-2012) - Esaote : Manufacturer, apparatus for blood pressure measurement (2011-2012)

- ATCOR : Manufacturer, apparatus for blood pressure measurement (2011-2012)

Mancia Giuseppe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Cardiovascular Area (2010) - Astra Zeneca : Cardiovascular area (2010-2011)

- Boehringer-Ingelheim : cardiovascular area (2010-2011)

- Novartis : cardiovascular area (2010-2011)

- Servier : cardiovascular area (2010-2011)

- Sanofi Aventis : cardiovascular area (2010-2011)

- Menarini : cardiovascular area (2010-2011)

- Takeda Pharmaceuticals : cardiovascular area (2010-2011)

- Bayer Schering Pharma : cardiovascular area (2010-2011)

- Recordati International : cardiovascular area (2011)

- Bayer AG : Cardiovascular area (2012)

- Boehringer-Ingelheim : Cardiovascular area (2012)

- Daiichi Sankyo : Cardiovascular area (2012)

- Medtronic : Cardiovascular area (2012)

- Novartis : Cardiovascular area (2012)

- Servier : cardiovascular area (2012)

10/2014/06/2013



karine_villanese

Typewritten Text


Mancia Giuseppe - Menarini : Cardiovascular area (2012)

- Takeda Pharmaceuticals : cardiovascular area (2012)

- Recordati International : cardiovascular area (2012)

14/05/2013 Position: (instead of the position which appears now):

Emeritus Professor, University of Milano-Bicocca, Milano, Italy

Director, Center of Epidemiology and Clinical Trials, IRCCS Istituto Auxologico Italiano, Milano, Italy


Manolis Athanasios John A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Hypertension, (2010-2011-2012) - Menarini : hypertension, heart failure (2010-2011-2012)

D - Research funding (departmental or institutional). - Bayer : AF (2010-2011-2012) - Boehringer-Ingelheim : AF (2010-2011-2012)

- GlaxoSmithKline : Coronary Heart Diseaese (2010-2011-2012)

- Servier : Heart Failure (2010-2011-2012)

13/05/2013 No new information


11/2014/06/2013



Narkiewicz Krzysztof A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Hypertension (2010-2011-2012) - Daiichi Sankyo : Hypertension (2010-2011-2012)

- Medtronic : Hypertension (2011-2012)

- Novartis : Hypertension (2010-2011-2012)

- Servier : Hypertension (2010-2011-2012)

- Sanofi Aventis : Hypertension (2010-2011)

- Menarini : Hypertension (2010-2011-2012)

- Merck Sharp & Dohme : Hypertension (2010-2011)

- Bayer Schering Pharma : Hypertension (2010-2011)

- Krka : Hypertension (2010-2011-2012)

17/05/2013 Same relationships as reported previously, i.ed. no changes to declare.


Nilsson Peter M A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novo Nordisk : Diabetes treatment (2011-2012) - Boehringer-Ingelheim : linagliptin (2011-2012)

- Asstrazeneca : Saxagliptin (2011-2012)

- Merck Sharp & Dohme : sitagliptin, anacetrapib (2010-2011-2012)

- Novartis : Vildagliptin (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : vildagliptin (2010-2011-2012)

12/2014/06/2013



Nilsson Peter M - Boehringer-Ingelheim : linagliptin (2010)

- Astra Zeneca : saxagliptin (2010)

- Pfizer : atorvastatin (2010)

14/05/2013 'I have the same relationships as 2012 i.e. no changes to declare'

Peter M Nilsson14/05/2013 'I have the same relationships as 2012 i.e. no changes to declare'

Peter M Nilsson


Redon Josep A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Boehringer-Ingelheim : Antihypertensive drugs (2011)

- Novartis : Antihypertensive drugs (2011)

- Menarini : Antihypertensive drugs (2011)

- MSD : Antihypertensive drugs (2011)

- Astra Zeneca : Diabetes (2012)

- Bristol Myers Squibb : Diabetes (2012)

- Boehringer-Ingelheim : Hypertension (2012)

- Menarini : Hypertension (2012)

- MSD : Hypertension (2012)

- Daiichi Sankyo : Antihypertensive drugs (2011)

- Daiichi Sankyo : Hypertension (2012)

Ruilope Luis Miguel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Advisor (2012)

13/2014/06/2013



karine_villanese

Typewritten Text


Ruilope Luis Miguel - GlaxoSmithKline : Advisor (2012)

- Bristol Myers Squibb : Advisor (2012)

- Medtronic : Advisor and speaker (2012)

- Servier : Advisor and speaker (2012)

- Menarini : Advisor and speaker (2012)

- Relypsa : Advisor and speaker (2012)

- Takeda Pharmaceuticals : Advisor and speaker (2012)

- Astra Zeneca : Cardiovascular (2010)

- Bayer : Cardiovascular (2010-2011)

- Boehringer-Ingelheim : cardiovascular (2011)

- Daiichi Sankyo : Cardiovascular (2010-2011)

- Medtronic : Cardiovascular (2010)

- Novartis : Cardiovascular (2010)

- Pfizer : Cardiovascular (2010)

- Menarini : Cardiovascular (2010-2011)

- Esteve : cardiovascular (2011)

- Takeda Pharmaceuticals : Cardiovascular (2010-2011)

- Almiral Spain : Cardiovascular (2011)

- Ardian : Cardiovascular (2010)

- Ardian : catheter mediated renal denervation (2011)

- Daiichi Sankyo : Chairman study SEVITENSION (2012)

- Relypsa : CKD (2011)

- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : CKD (2011)

- BMS : Diabetes (2010-2011)

14/2014/06/2013



Ruilope Luis Miguel - F. Hoffman La Roche Ltd : Member Executive Committee ALEPREVENT study (2012)

- Bayer Healthcare : Member Executive Committee ARRIVE study (2012)

- Medtronic : renal denervation (2011)

- Astra Zeneca : Speaker and Advisor (2012)

- Novartis : Speaker and advisor (2012)

- Bayer AG : Speaker and Advisor (2012)

- Boehringer-Ingelheim : Cardiovascular (2010)

- Boehringer-Ingelheim : Cardiovascular (2011)

28/05/2013 Similar to the previous one 2012, except that Otsuka is not present.


Schmieder Roland A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Nephrology and Hypertension (2010-2011-2012) - Boehringer-Ingelheim : Nephrology and Hypertension (2010-2011-2012)

- Daiichi Sankyo : Nephrology and Hypertension (2010-2011-2012)

- Medtronic : Nephrology and Hypertension (2011-2012)

- Novartis : Nephrology and Hypertension (2010-2011-2012)

- Servier : Nephrology and Hypertension (2010-2011-2012)

- Chiesi Pharma : Nephrology and Hypertension (2010)

- Berlin Chemie AG : Nephrology and Hypertension (2010-2011-2012)

- Takeda Pharmaceuticals : Nephrology and Hypertension (2010-2011-2012)

- Bristol Myers Squibb : Nephrology and Hypertension (2010-2011-2012)

15/2014/06/2013



Schmieder Roland D - Research funding (departmental or institutional). - BMS : Nephrology and Hypertension (2011-2012) - Daiichi Sankyo : Nephrology and Hypertension (2011-2012)

- Medtronic : Nephrology and Hypertension (2011-2012)

- Novartis : Nephrology and Hypertension (2011-2012)

- Deutsche Forschungsgemeinschaft : Nephrology and Hypertension (2010)

- BMBF - German Ministry of Research and Education : Nephrology and Hypertension (2010)

- BMBF - German Ministry of Research and Education : Nephrology and Hypertension (2011-2012)

14/05/2013 one additional financial Declaration for 2013:

D - Research Funding Company : Boehringer Ingelheim Product or Therapeutic Area : Nephrology and Hypertension


Sirnes Per Anton A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - NORMA onbehalf of Janssen Cilar : Invest fee CANVAS study (2012)

- Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)

- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012)

- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012)

- Merck Sharp & Dohme : Investigartor fee HPS2-THRIVE STUDY (2012)

- Boehringer Ingelheim : Investigator Fee Relyable study (2012)

- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)

- Bayer : clinical studies atrial fibrillation investigator fee (ROCKET) (2010)

16/2014/06/2013



Sirnes Per Anton - Merck Sharp & Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2010-2011)

- GlaxoSmithKline : investigator fee, clinical study , SCAD (2010-2011)

- Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010)

- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2010-2011)

- Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010-2011)

- Boehringer-Ingelheim : investigator fee, clinicla study, AF (RELY. RELYABLE) (2010)


Sleight Peter A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Aliskeren (2011-2012) - Sanofi Aventis : clopidogrel (2011)

- Novartis : DSMB (2010)

- Novo-Nordisk : DSMB (2010)

- Boehringer-Ingelheim : Hypertension Dabigatran (2011-2012)

- Novo-Nordisk : Insulin (2011-2012)

- Abbott : Lipids (2011-2012)

- Genzyme : Lipids (2011-2012)

- Boehringer-Ingelheim : occasional speaker fees (2010)

- Astra Zeneca : Hypertension (2011-2012)

- Merck Sharp & Dohme : Niacin Lipids (2011-2012)


17/2014/06/2013



karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

No new information

karine_villanese

Typewritten Text

karine_villanese

Typewritten Text

28/05/2013 COI same as 2012

Viigimaa Margus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Coagulation (2010-2011-2012) - GlaxoSmithKline : Coagulation (2010-2011-2012)

- Servier : Coronary heart disease (2010-2011)

- Merck Sharp & Dohme : Dyslipidemia (2010-2011-2012)

- Boehringer-Ingelheim : Hypertension (2010-2011-2012)

- Menarini : Hypertension (2010-2011-2012)

14/05/2013 No new information.


Waeber Bernard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Aliskiren (2011-2012) - Servier : Indapamide (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : atorvastatine (2011-2012) - Astra Zeneca : candesartan (2011-2012)

- Sanofi Aventis : irbesartan (2011-2012)

D - Research funding (departmental or institutional). - KaZ Europe : Blood pressure measuring device (2011-2012)

18/2014/06/2013



28/05/2013 Board of the Pfizer Foundation in SwitzerlandBoard of the Swiss Society of HypertensinCo-editor of the Journal PraxisMember of the Board of the journal "Revue médicale suisse"Member of the editorial board of the Journal of Cardiovascular Pharmacology


Zanchetti Alberto A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Cardiovascular (2010-2011-2012) - Novartis : Cardiovascular (2010)

- Menarini : Cardiovascular (2010-2011-2012)

- CVRx : Cardiovascular (2010-2011-2012)

- Recordati International : Cardiovascular (2010-2011-2012)

D - Research funding (departmental or institutional). - CVRx : Cardiovascular (2010-2011-2012)

14/05/2013 Same relationships as 2012 i.e. no changes to declare

14/05/2013 Same relationships as 2012 i.e. no chages to declare


Zannad Faiez A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : adreview (2010) - Novartis : aliskiren (2010-2011-2012)

- Alere : BNP (2010)

- Takeda Pharmaceuticals : diabetes (2012)

19/2014/06/2013



Zannad Faiez - Pfizer : eplerenone (2010-2011-2012)

- Boston Scientific : heart failure (2010-2011-2012)

- Servier : heart failure (2010-2012)

- St Jude Medical : heart failure (2010)

- Biotronik : heart failure (2012)

- Bayer Healthcare : heart failure (2010-2011-2012)

- Duke University : heart failure and diabetes (2010)

- Relypsa : K polymer (2010)

- Astra Zeneca : rosuvastatin (2010)

- Resmed : sleep apena (2012)

- Takeda Pharmaceuticals : thrombosis, diabetes, heart failure (2010)

E - Research funding (personal). - Roche Pharma : biomarker (2010-2011) - Roche Diagnostics : biomarker (2012)

- BG medicine : Galectin-3 (2010-2011)

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

20/2014/06/2013



karine_villanese

Typewritten Text


Agabiti-Rosei Enrico A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : hypertension, aliskiren (2011-2012) - Recordati International : Hypertension, enalapril + lercanidipine (2011-2012)

- Bayer AG : hypertension, nifedipine, telmisartan (2011-2012)

- Daiichi Sankyo : hypertension, olmesartan (2011-2012)

- Menarini : Hypertension, olmesartan, nebivolol,zofenopril (2011-2012)

- Boehringer-Ingelheim : vascular medicine, telmisartan, dabixatran (2011-2012)

D - Research funding (departmental or institutional). - Novartis : Hypertension, aliskiren (2011-2012) - Recordati International : Hypertension, enalapril + lercanidipine (2011-2012)

20/05/2013 same relationships as last year i.e. no changes to declare.enrico agabiti rosei


Ambrosioni Ettore A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Menarini : speaker fees (2011)

14/05/2013same relationship as 2012 i.e. no changes to declare


1/2214/06/2013

Guidelines on Hypertension 2013 (TF31) - Reviewers


Anker Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer AG : Anti-coagulation in heart failure (2011) - BRAHMS GmbH : Biomarker in heart failure (2011-2012)

- BG medicine : Biomarker in heart failure (2011-2012)

- Novartis : Cachexia therapy (2011-2012)

- GSK : Cachexia therapy (2011-2012)

- GTx : Cachexia therapy (2011-2012)

- PsiOxus Therapeutics : Cachexia therapy in cancer (2011-2012)

- Reata : CKD therapy (2011)

- Abbott Vascular : Device heart failure (2012)

- Impulse Dynamics : Device in heart failure (2011)

- Impulse Dynamics : Device in heart failure (2012)

- LoneStar Heart : Device in heart failure (2011-2012)

- Abbott Vascular : Device Renal Failure (2011)

- Pluristem Therapeutics : DSMB - stem cells for muscle wasting (2012)

- Applied Clinical Intelligence, LLC : Endpoint adjudication COPD (2011-2012)

- Servier : Heart failure (2012)

- Menarini : Heart failure (2012)

- Cardiomems : Heart failure (2012)

- Bayer AG : Heart failure (2012)

- Medical Sensible : Heart failure (2012)

- Vifor International : iv Iron therapy for heart failure (2011-2012)

- Servier : Ivabradine heart failure (2011)

- Relypsa : K+ Resin (2011-2012)

- Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2012)

2/2214/06/2013



Anker Stefan - Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2011)

- Fresenius Nutrition : Pre-Cachexia therapy (2011)

- Amgen Inc : RED-HF (2011)

- Novartis : SAB heart failure (2012)

- Amgen Inc : SAB heart failure (2012)

- St Jude Medical : Telemonitoring (2011-2012)

- Bosch AG Germany : Telemonitoring (2011-2012)

- SHL Telemedicine : Telemonitoring (2011)

- Cardiorentis : TRUE-AHF trial, executive committee (2012)

D - Research funding (departmental or institutional). - BRAHMS GmbH : Biomakers in heart failure (2011) - Metabolic Research srl (Italy) : Cachexia nutrition research (2012)

- Novartis : cachexia research (2012)

- PsiOxus Therapeutics : Cancer cachexia (2011-2012)

- Novartis : CHF therapy development (2011)

- Vifor International : CHF therapy development (2011-2012)

- Bayer AG : CHF therapy development (2011-2012)

- Impulse Dynamics : Heart failure (2012)

- Abbott Vascular : Heart failure (2012)

- Medical Sensible : Heart failure (2012)

- Abbott Nutrition : Nutrition education (2011)


3/2214/06/2013



06/06/2013 under A:

BG Medicine

Professional Dietetics / Solartium Dietetics GmbH:now no longer active

Amgen Inc:now no longer active

GSK:now no longer active

Servier

Janzen (J&J) = new

under D -- research funding

PsiOxus:now no longer support

Bayer Medical Sensible:now no longer support

Bauersachs Johann A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2011-2012) - Daiichi Sankyo : ACS (2011-2012)

- Lilly : ACS (2011-2012)

4/2214/06/2013



Bauersachs Johann - Bayer : Afib (2011-2012)

- Boehringer-Ingelheim : Afib (2011-2012)

- Bristol Myers Squibb : Afib (2011-2012)

- Actavis : CAD (2011-2012)

- Merck Sharp & Dohme : CAD, Afib (2011-2012)

- Pfizer : Heart Failure, Afib (2011-2012)

- Medtronic : Heart Failure, Hypertension (2011-2012)

- Berlin Chemie AG : Hypertension, CAD (2011-2012)

- Novartis : Hypertension, Heart Failure (2011-2012)

D - Research funding (departmental or institutional). - Bayer : Heart Failure (2011-2012) - Pfizer : Heart Failure (2011-2012)

- Sanofi Aventis : Heart Failure (2011-2012)

- Actavis : Heart Failure, CAD (2011-2012)



Brguljan Jana None

Caulfield Mark A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Renal Denervation (2011-2012)

5/2214/06/2013



karine_villanese

Typewritten Text


Caulfield Mark B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : a (2011-2012) - Takeda Pharmaceuticals : a (2011-2012)

D - Research funding (departmental or institutional). - Servier : Hypertension (2011-2012) - Takeda Pharmaceuticals : Hypertension (2011-2012)

Clement Denis None

15/05/2013 There are no changes compared to 2012.


Coca Antonio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Aliskiren; Valsartan, combos (2011-2012) - Takeda Pharmaceuticals : Azilsartan (2012)

- Recordati International : Azilsartan; Lercanidipine; combos (2012)

- Sanofi Aventis : Irbesartan, combos (2011)

- Chiesi Pharma : Manidipine, Delapril (2011-2012)

- Menarini : Nevibolol; Olmesartan, combos (2011-2012)

- Ferrer Internacional : Torasemide; CardioIncode microchips (2011-2012)

- Esteve : Valsartan, Aliskiren, combos (2011-2012)



6/2214/06/2013



karine_villanese

Typewritten Text


de Buyzere Marc None

13/05/2013 same relationships as 2012 i.e. no changes to declare


De Geest Sabina M A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : Cancer (2011-2012)B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : transplantation (2011-2012) - Biotest : transplantation (2011-2012)

D - Research funding (departmental or institutional). - Novartis : Transplantation (2011-2012) - Roche Pharma : Transplantation (2011-2012)

- Astellas : Transplantation (2011-2012)

Derumeaux Genevieve Anne

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Bosentan (2011-2012) - Medtronic : CRT (2011)

- Toshiba medical imaging : Echocardiography (2011-2012)

- Servier : Ivabradine (2011-2012)

7/2214/06/2013



karine_villanese

Typewritten Text


Derumeaux Genevieve Anne

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Benfluorex (2012) - Medtronic : CRT (2011-2012)

- Bayer Healthcare : Pulmonary hypertension and heart failure (2011-2012)

- Actelion : Pulmonary hypertension and systemic scleroderma (2011-2012)

D - Research funding (departmental or institutional). - BRAHMS GmbH : Biomarkers (2011) - TROPHOS : Cardioprotection (2011)

- Astra Zeneca : Cohort of myocardial infarction patients (2011-2012)

Erdine Serap A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Therapeutic Area (2011-2012) - Daiichi Sankyo : Therapeutic Area (2011-2012)

- Novartis : Therapeutic Area (2011-2012)

- Abbott Laboratories : Therapeutic Area (2011-2012)

Farsang Csaba A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : diabetes (2011-2012) - Servier : hypertension (2011-2012)

- Richter G. Rt. Hungary : hypertension (2011-2012)

- EGIS Rt. Hungary : hypertension, diabetes (2011-2012)

13/05/2013 Only one change for the year 2013: AMGEN should be omitted. Otherwise use the previous declaration


8/2214/06/2013



karine_villanese

Typewritten Text


karine_villanese

Typewritten Text


Funck-Brentano Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis CH : Adjudication Committee on an immunosuppressant (2011-2012) - Lundbeck : Cardiac safety of an antidepressant (2011-2012)

- Shire HGT : Cardiac safety of an antidiarrheal drug (2012)

- Pierre-Fabre : Cardiac Safety of non-cardiovasclar products (2011-2012)

- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012) - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012) - MMV (CH) : Cardiac Saftey of an antimalarial drug (2011)

- Santhera (CH) : Cardiac Saftey of an antimalarial drug (2011)

- Sigma Tau : Cardiac Saftey of an antimalarial drug (2011)

- MMV (CH) : Cardiac Saftey of two antimalarial drugs (2012)

- Actelion : Consulting on the potential udevelopement of a calcium inhibitor (2012)

- BMS : Discussion on an educational program for stroke prevention in AF (2012)

- TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2011)

- CEPHALON : DSMB in an oncology phase IIb trial (2011-2012)

- Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2011)

- Intracellular Therapies USA : Psyhotropic drug developement (2011)

- Medco Health Solutions : co-investigator of a phase I study of an iv antiplatelet drug - payment to the hospital (2012)

26/05/2013 No new info since my DOI of 27/02/2013


9/2214/06/2013



Gerc Vjekoslav None

Germano Giuseppe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Servier : Hypertension (2011)

- Takeda Pharmaceuticals : Hypertension (2011)

- Recordati International : Hypertension (2011)

30/05/2013 'same relationships as 2012 i.e. no changes to declare'


Gielen Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Genzyme : Fabry disease (2011) - Astra Zeneca : Lectures 2012 (2012)

- Novartis : Heart failure, antihypertensives (2011)

Gillebert Thierry A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Boehringer-Ingelheim : Afib (2011)

- Astra Zeneca : Heart Failure (2011)

D - Research funding (departmental or institutional). - Astra Zeneca : Unrestricted grant Asklepios study (2011-2012)

10/2214/06/2013



karine_villanese

Typewritten Text


Gillebert Thierry - Merck Sharp & Dohme : Unrestricted grant Asklepios study (2011-2012)

04/06/2013 none


Haller Hermann A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : hypertension (2011-2012) - Menarini : hypertension (2011-2012)

- Amgen : kidney (2011-2012)

- BMS : kidney (2011-2012)

- Pfizer : kidney (2011-2012)

- Sanofi Aventis : kidney (2011-2012)

- Roche Pharma : kidney (2011-2012)

- Astellas : kidney (2011-2012)

- Genzyme : kidney (2011-2012)

- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : kidney (2011-2012)

- Roche Diagnostics : kidney (2011-2012)

- Noxxon : kidney (2011-2012)

- MedWiss : kidney (2011-2012)

- Alexion : kidney (2011-2012)

- Phenos : kidney (2011-2012)

- Novartis : kidney and hypertension (2011-2012)

- Astra Zeneca : kidney and hypertension (2011-2012)

11/2214/06/2013



Haller Hermann - Bayer Schering Pharma : kidney and hypertension (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Cyclosporin (2011-2012) - Alexion : Eculizimab (2011-2012)

Hoes Arno A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012) - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012) - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)

03/06/2013 no changes to declare


12/2214/06/2013



karine_villanese

Typewritten Text


Jordan Jens A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Diabetes (2011-2012) - Novartis : Hypertension/ Heart Failure (2011-2012)

- Vivus : Obesity (2012)

- Riemser : Obesity (2011-2012)

Kahan Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : CV (2011-2012)

13/05/2013 Please update with new information on the following (no other changes):

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.

Company : Servier, Celldon Corp, Medtronic

Product or Therapeutic Area : Cardiovascular


Komajda Michel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : cardio metabolic (2012) - Sanofi Aventis : cardio metabolic (2012)

- Focus : cardiology (2012)

- Nile Therapeutics : CDNP (2012)

- Servier : Ivabradine (2011-2012)

- Duke University : Nesiritide (2011)

13/2214/06/2013



karine_villanese

Typewritten Text


Komajda Michel - Johnson & Johnson : Nesiritide (2012)

- PLB organisation : organisation (2011)

- Menarini : Ranolazine (2011-2012)

- Torrent : TRC 4186 (2011)

Lovic Dragan None

14/05/2013 I have nothing to declare, there is no conflict of interest.

Additional Information declaredfor 2013 January - May

Mahrholdt Heiko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Institut für Herzinfarktforschung Ludwigshafen, Germany : Consultant (2011-2012)D - Research funding (departmental or institutional). - Robert Bosch Foundation : Research Grants (2011-2012)

Olsen Michael Hecht A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Novo Nordisk : Lecture (2012)

- Novo Nordic Foundation : Research within cardiovascular target organ damage (2012)

Ostergren Jan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneD - Research funding (departmental or institutional). - Novartis : Aliskiren (2011-2012)

14/2214/06/2013



karine_villanese

Typewritten Text


karine_villanese

Typewritten Text


karine_villanese

Typewritten Text


31/05/2013 No changes to declare for 2013


Parati Gianfranco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Hypertension (2012) - Speaker s fee, Bayer : Hypertension (2011)

Perk Joep None


Polonia Jorge Manuel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Speaker: Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Jaba Recordati, Medinfar, Menarini, Novartis, Sanofi-Aventis,Servier : antihypertensive drugs (several); oral antidiabetic drugs (2011) - Speaker: Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Jaba Recordati, Medinfar, Menarini, Novartis, Sanofi-Aventis,Servier : Antihypertensive drugs and antidiabetic drugs several (2012)

20/05/2013 Same relationships as January 2013 i.e. no changes to declare


15/2214/06/2013



karine_villanese

Typewritten Text


karine_villanese

Typewritten Text


Popescu Bogdan Alexandru A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging (2011-2012)

03/06/2013 Same relationships as declared on Feb 26, 2013, i.e. no changes to declare.


Reiner Zeljko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulants (2011) - Astra Zeneca : antilipemics (2011-2012)

- Pfizer : antilipemics (2011)

- Sanofi Aventis : antilipemics (2011)

- Abbott Laboratories : antilipemics (2011-2012)

- Bayer : Antithrombotcs (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Antilipemics (2012) - Merck Sharp & Dohme : Antilipemics (2012)

- Merck Sharp & Dohme : antilipemics (2011)

31/05/2013 No changes to declare in 2013


16/2214/06/2013



Ryden Lars A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Cardiology; Course organisation, lecture (2011-2012) - Sanofi Aventis : Daibetes and cardiovascular disease. Advisor boards, lecture fees (2011)

- BMS : Diabetes and cardiovascular disease. Advisory committee fee (2011-2012)

- Astra Zeneca : Diabetes and cardiovascular disease; Advisory Board and occasional lecture fees (2011-2012)

- Roche Pharma : Diabetes and cardiovascular disease; Consultant, lecture fees (2011-2012)

- Bayer : Diabetes and cardiovascular disease; Lecture fees (2012)

- Bayer : Diabetes and cardiovascular disease; Lecture fees (2011)

- Amgen : Member DSMB (2011)

D - Research funding (departmental or institutional). - Roche Pharma : Diabetes and cardiovascular disease (2012) - Astra Zeneca : Cardiology (2011)

- Roche Pharma : Cardiology (2011)

13/05/2013 I have become honorary member of the Moldavian and the Romanian Societies of Cardiology in April 2013.

13/05/2013 Besides the new honorary memberships no further changes,


Sirenko Yuriy None

Stanton Alice A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Rox Medical : Cardiovascular Interventions (2011-2012) - Bayer : Cardiovascular Therapeutics (2011)

- Boehringer-Ingelheim : Cardiovascular Therapeutics (2011-2012)

17/2214/06/2013



karine_villanese

Typewritten Text


Stanton Alice - Daiichi Sankyo : Cardiovascular Therapeutics (2011-2012)

- Novartis : Cardiovascular Therapeutics (2011)

- Pfizer : Cardiovascular Therapeutics (2011)

- Servier : Cardiovascular Therapeutics (2011-2012)

- Menarini : Cardiovascular Therapeutics (2011-2012)

- Takeda Pharmaceuticals : Cardiovascular Therapeutics (2011-2012)

- Bristol Myers Squibb : Cardiovascular Therapeutics (2011)

- Sigma Tau : Cardiovascular Therapeutics (2011)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Rox Medical : Cardiovascular Interventions (2012) - Bayer AG : Cariovascular Therapeutics (2012)



Struijker-Boudier Harry A J A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Cardiovascular (2011-2012) - Merck-Serono : Cardiovascular (2011-2012)




18/2214/06/2013



Tendera Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2011-2012) - Amgen : Darbopoietin (2011-2012)

- Servier : Ivabradine, Phase II investigational products (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2011-2012) - TIMI group : Rivaroxaban (2011)

13/05/2013 No new info.


Tsioufis Costas None

15/05/2013 I have received payment of Travel Expenses, Research Grands and Honoraria from Medtronic, St Jude, Novartis, Astra Zeneca, Bayer, Abbott.


van de Borne Philippe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Bayer : small fee for writing a chapter (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Advisory board (2011-2012)

19/2214/06/2013



van de Borne Philippe - Bayer Schering Pharma : Advisory board (2011-2012)

- Astra Zeneca : Chair chronic cardiovascular disease (for the department) (2011-2012)

- Boehringer-Ingelheim : Education grant (for the department) (2011)

- Medtronic Foundation : Education grant (for the department) (2011)

- Daiichi Sankyo : Speakers fee (2011-2012)

D - Research funding (departmental or institutional). - Dr . Tagnon fund : Renal denervation (2011-2012)




Vlachopoulos Charalambos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Statin (2011-2012) - Bayer : Testosterone (2012)



Volpe Massimo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : aliskiren, valsartan (2011-2012) - Sanofi Aventis : dronedarone (2011-2012)

20/2214/06/2013



Volpe Massimo - Daiichi Sankyo : olmesartan (2011-2012)

- Menarini : olmesartan (2011-2012)

- Boehringer-Ingelheim : telmisartan (2011-2012)

- Bayer Healthcare : telmisartan (2011-2012)

D - Research funding (departmental or institutional). - Daiichi Sankyo : no specific product (2011-2012) - Novartis : no specific product (2011-2012)



Wood David Allan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Kowa : Atherosclerosis (2011) - Astra Zeneca : Crestor - Lipid Modification (2011)

- Astra Zeneca : Lipid modification (2012)

- Merck Sharp & Dohme : Niacin - Lipid Modification (2011-2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - EMD Communications China : Training Course in Preventive Cardiology (2012)D - Research funding (departmental or institutional). - European Society of Cardiology : EUROASPIRE IV (2012) - Pfizer : Varenicline - smoking cessation (2011)


21/2214/06/2013



04/06/2013 Following changes to the List of the ESC bodies membership section:

REMOVE: ESC Board Members, ESC Business Model Task Force, ESC Training and Research Grants Committee, Advisory Group for the ESC Cardiovascular Research Foundation, 5th Joint European Task Force on CVD Prevention.ADD: CardioScape, ESC Strategy Committee.


22/2214/06/2013



Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Siemens Healthcare : CT (2012) - Servier : Imaging (2012)

- Guerbet : Imaging (2012)

14/05/2013 Same relationships as last year, nothing new to declare.

Additional Information declared for 2013 January - May:

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Bosentan for PAH treatment in congenital heart disease (2012) - Edwards Lifesciences : transcatheter valve implantation (2012)

13/05/2013 no changes compared to 2012


Bax Jeroen A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneD - Research funding (departmental or institutional). - Servier : Farma (2012)

1/1414/06/2013

Committee for Practice Guidelines 2012-2014


Bax Jeroen - Edwards Lifesciences : Heart Valves (2012)

- GE Healthcare : Imaging (2012)

- Lantheus Inc : Imaging (2012)

- Boston Scientific : Pacing (2012)

- Medtronic : Pacing (2012)

- St Jude Medical : Pacing (2012)

- Biotronik : Pacing (2012)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Aspirin, rivaroxaban (2012) - Roche Pharma : Dalcetrapib (2012)

- Novartis : Heart Failure and elinogrel (2012)

- Daiichi Sankyo : Prasugrel (2012)

- Eli Lilly : Prasugrel (2012)

- Astra Zeneca : Ticagrelor (2012)

E - Research funding (personal). - Astra Zeneca : Ticagrelor (2012)

14/05/2013 No additional information to disclose in addition to my February 2013 disclosure


Deaton M Christi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None

2/1414/06/2013



karine_villanese

Typewritten Text


Deaton M Christi D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)

13/05/2013 Funding from Novo Nordisk has ended, no other changes to report

13/05/2013 no other new information


Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012)

C - Receipt of royalties for intellectual property. - Astra-Zeneca : Ticagrelor (2012)

13/05/2013 Only the product of Menarini should be Olmesartan.That is all I can change.Thank you very much.


Fagard Robert None



3/1414/06/2013



Ferrari Roberto A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoaguland and diabetes. Dagabitran (2012) - Medical Trials Analysis : Consultant in Clinical Trials (2012)

- Servier : Myocardial ischamia and heart failure. Perindopril, ivabradine, alodipine, trimetazidine (2012)

D - Research funding (departmental or institutional). - Schering-Plough : Anti-platelet agent TRACER (2012) - Fondazione Salvatore Maugeri : General (2012)

- Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012)



Hasdai David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None - Boehringer-Ingelheim : Pradaxa (2012)

- Bayer : Rivaroxiban (2012)

- Astra Zeneca : Ticagrelor (2012)

14/05/2013 none


4/1414/06/2013



Hoes Arno A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012) - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012) - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)

03/06/2013 no changes to declare


Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : cardiovascular (2012) - Boehringer-Ingelheim : cardiovascular (2012)

5/1414/06/2013



Kirchhof Paulus - Daiichi Sankyo : cardiovascular (2012)

- Medtronic : cardiovascular (2012)

- Pfizer : cardiovascular (2012)

- St Jude Medical : cardiovascular (2012)



- Merck Sharp & Dohme : cardiovascular (2012)

- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular (2012) - Bayer Healthcare : cardiovascular (2012)

- Portola Pharmaceuticals : cardiovascular (2012)

- BMS / Pfizer alliance : cardiovascular (2012)

D - Research funding (departmental or institutional). - St Jude Medical : cardiovascular (2012) - Sanofi Aventis : cardiovascular (2012)


14/05/2013 Consulting fees and honoraria 3M MedicaMEDA PharmaAstraZenecaBayer HealthcareBiosense WebsterBoehringer IngelheimDaiichi-SankyoGerman Cardiac SocietyMEDA Pharma


6/1414/06/2013



MedtronicMerckMSDOtsuka PharmaPfizer / BMSsanofiServierSiemensTAKEDA

In addition, I have received travelsupport for meetings from theEuropean Society of Cardiology (ESC),the European Heart RhythmAssociation (EHRA), a registeredbranch of ESC, and from the GermanAtrial Fibrillation CompetenceNETwork (AFNET)

Research Grants3M Medica / MEDA PharmaCardiovascular TherapeuticsMedtronicOMRONSANOFISt. Jude MedicalGerman Federal Ministry forEducation and Research (BMBF)Fondation LeducqGerman Research Foundation (DFG)European Union (EU)

Knuuti Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012)

7/1414/06/2013



Knuuti Juhani D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012)

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp & Dohme : Antistaphylococcic vaccine (2012)D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012)

- St Jude Medical : Cardiac valves (2012)

- Boston Scientific : Coronary stents (2012)

- Siemens Healthcare : Medical imaging (2012)

- Johnson & Johnson : Thoracoscopic devices (2012)



Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Heart Failure (2012)B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012)

8/1414/06/2013



karine_villanese

Typewritten Text


Lancellotti Patrizio - Abbott Vascular : MitraClip (2012)

Linhart Ales A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Arterial hypertension (2012) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012)

- GlaxoSmithKline : Atherosclerosis (2012)

- Merck Sharp & Dohme : Dyslipidemia (2012)

- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012)

- Shire HGT : Fabry disease (2012)

- Genzyme : Fabry disease (2012)

- Actelion : Pulmonary hypertension (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Shire HGT : Fabry disease (2012)

Nihoyannopoulos Petros None

Piepoli Massimo Francesco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)

13/05/2013 'same relationships as 2012 i.e. no changes to declare':


Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BMS : anticoagulant (2012)

9/1414/06/2013



karine_villanese

Typewritten Text


karine_villanese

Typewritten Text


Ponikowski Piotr - Boehringer-Ingelheim : anticoagulant (2012)

- Respicardia : anticoagulant (2012)

- Abbott Vascular : devices (2012)

- Amgen : heart failure (2012)

- Novartis : heart failure (2012)

- Johnson & Johnson : heart failure (2012)

- Bayer Healthcare : heart failure (2012)

- Vifor Pharma ltd : heart failure (2012)

- Corthera : heart failure (2012)

- Coridea : heart failure (2012)

- Pfizer : heart failure, anticoagulant (2012)

- Servier : heart failure, coronary artery disease (2012)

D - Research funding (departmental or institutional). - Vifor Pharma ltd : heart failure (2012)

14/05/2013 update to DOI 2012:- Abbott Vascular


Sirnes Per Anton A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NORMA onbehalf of Janssen Cilar : Invest fee CANVAS study (2012) - Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)

10/1414/06/2013



Sirnes Per Anton - GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012)

- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012)

- Merck Sharp & Dohme : Investigartor fee HPS2-THRIVE STUDY (2012)

- Boehringer Ingelheim : Investigator Fee Relyable study (2012)

- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)


Tamargo Juan Luis A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)

Tendera Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Aspirin, Rivaroxaban (2012) - Amgen : Darbopoietin (2012)

- Servier : Ivabradine, Phase II investigational products (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradine, Phase II investigational products (2012)

13/05/2013 No new info.


11/1414/06/2013



karine_villanese

Typewritten Text


karine_villanese

Typewritten Text


Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Cardiomems : implanted pulmonary artery pressure sensor (2012) - United Therapeutics : Pulmonary arterial hypertension (2012)

- GSK : pulmonary arterial hypertension - ambrisentan (2012)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012)

- Lilly : pulmonary arterial hypertension - tadalafil (2012)

- AOP : Pulmonary arterial hypertension - treprostinil (2012)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2012)

- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Pulmonary hypertension (2012) - Sanofi Aventis : Thromboembolic disease (2012)

Wijns William A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NoneB - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : device (2012) - Boston Scientific : device (2012)

- Edwards Lifesciences : device (2012)

- Medtronic : device (2012)

- St Jude Medical : device (2012)

- Biotronik : device (2012)

- Terumo Inc : device (2012)

- Abbott Vascular : device (2012)

- Cordis : device (2012)

12/1414/06/2013



karine_villanese

Typewritten Text


Wijns William - Orbus Nech : device (2012)

- MICELL : device (2012)

- Vessix : device (2012)

- Tryton : device (2012)

- GlaxoSmithKline : drug (2012)

- Astra Zeneca : pharma (2012)

D - Research funding (departmental or institutional). - Cardio3 Biosciences : cell therapy (2012) - Boston Scientific : device (2012)

- Medtronic : device (2012)

- St Jude Medical : device (2012)

- Biotronik : device (2012)

- Abbott Laboratories : device (2012)

- MICELL : device (2012)

- Therabel : drug (2012)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet drug (2012) - Eli Lilly : Antiplatelet drug (2012)

- Abbott : Stent (2012)

- Biosensors : Stent (2012)

- Boston Scientific : Stent (2012)

- Medtronic : Stent (2012)

- Biotronik : Stent (2012)

- Cordis : Stent (2012)

13/1414/06/2013



karine_villanese

Typewritten Text


Windecker Stephan - Edwards Lifesciences : TAVI (2012)

D - Research funding (departmental or institutional). - St Jude Medical : OCT (2012) - Abbott : Stent (2012)

- Biosensors : Stent (2012)

- Medtronic : Stent (2012)

- Biotronik : Stent (2012)

- Cordis : Stent (2012)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : Help in Design Echocardiographic protocol (2012) - Merck Sharp & Dohme : Lecture (2012)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - FP7 EU research program : CV Imaging (2012)C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2012)

13/05/2013 Same



14/1414/06/2013



karine_villanese

Typewritten Text


Guidelines on Hypertension 2013 (TF31) - TF …19/05/2013 Same relationships as last year, i.e., no...

Documents

Transcript of Guidelines on Hypertension 2013 (TF31) - TF …19/05/2013 Same relationships as last year, i.e., no...